No Data
No Data
Basal Egg Organism: Basal Egg Organism: Third Quarter Report 2024
Egg Biosciences: third quarter report 2024
Getein Biotech,Inc (603387.SH) released its performance for the first three quarters, with a net income of 0.202 billion yuan, a 11.69% year-on-year decrease.
Getein Biotech, Inc. (603387.SH) disclosed its third quarter report for 2024, achieving a revenue of 8....
Getein Biotech, Inc (603387.SH): The net income for the first three quarters was 0.202 billion yuan, a year-on-year decrease of 11.69%.
On October 30, Gleonhui announced its third-quarter report for 2024, with the company's revenue for the first three quarters of 0.88 billion yuan, a 12.10% year-on-year decrease; net income attributable to shareholders of listed companies was 0.202 billion yuan, a 11.69% year-on-year decrease; and basic earnings per share were 0.40 yuan.
Getein Biotech, Inc. (603387.SH): Its holding subsidiary Jingchuan Diagnostics has been delisted from the National Equities Exchange and Quotations system for small and medium-sized enterprises nationwide.
Getein Biotech,Inc (603387.SH) announced on October 24th that, according to the termination listing decision made by the National Equities Exchange and Quotations Co., Ltd., Jingchuan Diagnosis did not raise objections to the termination of listing matters to the National Equities Exchange and Quotations Co., Ltd. within the corresponding period, Jingchuan Diagnosis's stocks resumed trading and entered the delisting and reorganization period starting from October 10, 2024, which lasts for 10 trading days, with the final trading date being October 23, 2024. As of the disclosure date of this announcement, Jingchuan Diagnosis's delisting and reorganization period has ended, and Jingchuan Diagnosis's stocks were delisted on October 24, 2024.
Getein Biotech (SHSE:603387) Sheds CN¥507m, Company Earnings and Investor Returns Have Been Trending Downwards for Past Three Years
No Data
No Data